RE: RE: RE: RE: RE: KaydayTheoretically, the average score could be higher. The inclusion criteria was modified for the Phase 2b trial, in particular the NIHSS score range was restricted to those between 8-20. However, the lower doses of EPO in cohort 1 and 2 may show a lower level of improvement. This does not matter as the purpose of giving various doses is to find the optimal dose at which the most improvement is shown. There is a "point of diminishing returns" with most drug therapies and the window for the optimum dose can be quite small. Now if significant improvement was seen at a very low dose of EPO, that would be really something to celebrate. Guess we will know soon enough:)